Novel highly selective TAF1 inhibitor

Novel modulator of cell death signal transduction pathways, reducing the cytotoxicity of anthrax lethal toxin (LT)

Broad-spectrum, fifth-generation cephalosporin antibiotic, inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall

beta-Lactamase-stable, broad-spectrum, third-generation cephalosporin antibiotic with antibacterial activity

Broad-spectrum fourth-generation cephalosporin antibiotic

Fourth-generation cephalosporin

Third-generation broad spectrum antibiotic against both gram-positive and gram-negative microorganisms

Broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin antibiotic, inhibiting bacterial cell wall synthesis via inhibition of cross-linking of peptidoglycans

Second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

Third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

First-generation cephalosporin antibiotic and interleukin 15 inhibitor, specifically interacting with interleukin 15 (IL-15) receptor subunit α (IL-15Rα) and to inhibit IL-15-dependent TNF-α and IL-17 synthesis, showing inhibitory activity against all of

Novel highly selective inhibitor of multidrug resistance protein 4 (MRP4)

Potent Antagonist for the Human Thyrotropin Receptor (TSHR)

Highly permeable non-Pglycoprotein substrate

Novel anti-hepatitis B virus (HBV) agent

Novel photoaffinity probe for cyclin-dependent kinase (CDK) family

Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel potent CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel highly potent, selective, permeable CDK8 inhibitor

Novel inhibitor of CDK8

Novel potent and selective inhibitor of CDK8, also modulating CDK19